Home > Documents in Process > Early brain-wide disruption of sleep microarchitecture in amyotrophic lateral sclerosis. > print

001     283123
005     20260105130536.0
024 7 _ |a 10.1172/JCI194555
|2 doi
024 7 _ |a pmid:41196652
|2 pmid
024 7 _ |a pmc:PMC12721911
|2 pmc
024 7 _ |a 0021-9738
|2 ISSN
024 7 _ |a 1558-8238
|2 ISSN
037 _ _ |a DZNE-2026-00019
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lang, Christina
|0 P:(DE-2719)9002237
|b 0
|e First author
|u dzne
245 _ _ |a Early brain-wide disruption of sleep microarchitecture in amyotrophic lateral sclerosis.
260 _ _ |a Ann Arbor, Mich.
|c 2026
|b ASCJ
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767602743_32743
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a FUNDING: Agence Nationale de la Recherche (ANR); Fondation Thierry Latran; Association Francaise de Recherche sur la sclérose latérale amyotrophique; Association Française contre les myopathies; TargetALS; and Joint Program on Neurodegenerative Diseases Research (JPND).
520 _ _ |a BACKGROUNDAmyotrophic lateral sclerosis (ALS), the major adult-onset motor neuron disease, is preceded by an early period unrelated to motor symptoms, including altered sleep, with increased wakefulness and decreased deep nonrapid eye movement (NREM). Whether these alterations in sleep macroarchitecture are associated with - or even precede - abnormalities in sleep-related EEG features remains unknown.METHODSHere, we characterize sleep microarchitecture using polysomnography for patients with ALS (n = 33) and controls (n = 32) as well as for asymptomatic carriers of superoxide dismutase 1 (SOD1) or C9ORF72 mutations (n = 57) and noncarrier controls (n = 30). Patients and controls with factors that could confound sleep structure, including respiratory insufficiency, were prospectively excluded. The results were complemented in 3 ALS mouse models (Sod1G86R, FusΔNLS/+, and TDP-43Q331K).RESULTSWe observed a brain-wide reduction in the density of sleep spindles, slow oscillations, and K-complexes in patients with early-stage ALS and in presymptomatic gene carriers. These defects in sleep spindles and slow oscillations correlated with cognitive performance in both cohorts, particularly with scores on memory, verbal fluency, and language function. Alterations in sleep microarchitecture were replicated in 3 mouse models, and decreases in sleep spindles were rescued following intracerebroventricular supplementation of melanin-concentrating hormone (MCH) or by oral administration of a dual orexin receptor antagonist.CONCLUSIONSleep microarchitecture was associated with cognitive deficits and causally linked to aberrant MCH and orexin signaling in ALS.FUNDINGAgence Nationale de la Recherche (ANR); Fondation Thierry Latran; Association Francaise de Recherche sur la sclérose latérale amyotrophique; Association Française contre les myopathies; TargetALS; and Joint Program on Neurodegenerative Diseases Research (JPND).
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ALS
|2 Other
650 _ 7 |a Genetics
|2 Other
650 _ 7 |a Neuroscience
|2 Other
650 _ 7 |a Superoxide Dismutase-1
|0 EC 1.15.1.1
|2 NLM Chemicals
650 _ 7 |a C9orf72 Protein
|2 NLM Chemicals
650 _ 7 |a SOD1 protein, human
|2 NLM Chemicals
650 _ 7 |a C9orf72 protein, human
|2 NLM Chemicals
650 _ 7 |a Sod1 protein, mouse
|0 EC 1.15.1.1
|2 NLM Chemicals
650 _ 2 |a Amyotrophic Lateral Sclerosis: physiopathology
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: genetics
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: pathology
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Brain: physiopathology
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Superoxide Dismutase-1: genetics
|2 MeSH
650 _ 2 |a Superoxide Dismutase-1: metabolism
|2 MeSH
650 _ 2 |a C9orf72 Protein: genetics
|2 MeSH
650 _ 2 |a C9orf72 Protein: metabolism
|2 MeSH
650 _ 2 |a Sleep
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Polysomnography
|2 MeSH
650 _ 2 |a Mice, Transgenic
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
700 1 _ |a Guillot, Simon J
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Lule, Dorothee
|0 P:(DE-2719)9002172
|b 2
|u dzne
700 1 _ |a Balz, Luisa T
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Knehr, Antje
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Weydt, Patrick
|0 P:(DE-2719)9001116
|b 5
|u dzne
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 6
|u dzne
700 1 _ |a Kandler, Katharina
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Muller, Hans-Peter
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 9
|u dzne
700 1 _ |a Wassermann, Laura
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Da Cruz, Sandrine
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Roselli, Francesco
|0 P:(DE-2719)2812851
|b 12
|u dzne
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 13
|u dzne
700 1 _ |a Bolborea, Matei
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Dupuis, Luc
|0 P:(DE-HGF)0
|b 15
773 _ _ |a 10.1172/JCI194555
|g Vol. 136, no. 1, p. e194555
|0 PERI:(DE-600)2018375-6
|n 1
|p e194555
|t The journal of clinical investigation
|v 136
|y 2026
|x 0021-9738
856 4 _ |u https://pub.dzne.de/record/283123/files/DZNE-2026-00019.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/283123/files/DZNE-2026-00019.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002237
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002172
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001116
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9001951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001967
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812851
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812633
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN INVEST : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-02-16T10:37:49Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-02-16T10:37:49Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-02-16T10:37:49Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-02-16T10:37:49Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b J CLIN INVEST : 2022
|d 2024-12-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 0
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 1
920 1 _ |0 I:(DE-2719)1910001
|k AG Roselli
|l Metabolic Changes in Neurodegeneration
|x 2
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1910001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21